Alnylam Pharmaceuticals | ALNY - Selling And Administration Expenses


Alnylam Pharmaceuticals reported $282.51M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amgen USD 1.58B 354M Mar/2026
Arrowhead Research USD 41.74M 4.28M Mar/2026
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Incyte USD 328.1M 62.31M Mar/2026
Ionis Pharmaceuticals USD 151M 21M Mar/2026
Moderna USD 173M 135M Mar/2026
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Novartis USD 3.44B 132M Dec/2025
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.75B 455M Dec/2025
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Takeda JPY 292B 9.21B Mar/2026
Tectonic Therapeutic USD 3.44M 1.52M Dec/2025
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026
Xencor USD 82.12M 65.08M Mar/2026